Trial Profile

A Phase II (BRF113710) single-arm, open-label study of GSK2118436 (dabrafenib) in BRAF mutant metastatic melanoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Dec 2019 Results assessing long term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy using data from phase 2 and 3 clinical trials (BREAK-2, NCT01153763; BREAK-3, NCT01227889) published in the European Journal of Cancer
06 Jun 2017 Results of 5 year landmark analysis for phase II BREAK 2 (data cutoff date 17 Jun 2016) and phase III BREAK 3 (data cutoff date 6 Sep 2016) studies evaluating dabrafenib monotherapy in patients with BRAF V600-mutant melanoma, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
31 May 2014 Planned End Date changed from 1 Aug 2012 to 1 Feb 2016 as reported by ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com